Robert H Howland
Index: J. Psychosoc. Nurs. Ment. Health Serv. 50(1) , 16-8, (2012)
Full Text: HTML
Acute agitation in patients with schizophrenia or bipolar disorder is an important clinical management problem. Liquid concentrates, orally disintegrating tablets, and/or intramuscular formulations of several second-generation atypical antipsychotic drugs are available for treating acute agitation. Loxapine is an older first-generation antipsychotic drug that is approved for the treatment of schizophrenia. Staccato(®) loxapine is an investigational device system using a loxapine-coated heat source to administer loxapine by inhalation. Three multicenter, randomized, double-blind, placebo-controlled efficacy and safety studies of Staccato loxapine have been conducted in patients with acute agitation associated with schizophrenia or bipolar disorder. These studies found that inhaled loxapine was rapidly effective and generally well tolerated, although there are potential concerns about adverse pulmonary effects.Copyright 2012, SLACK Incorporated.
Structure | Name/CAS No. | Molecular Formula | Articles |
---|---|---|---|
![]() |
Loxapine succinate
CAS:27833-64-3 |
C22H24ClN3O5 |
Investigation of the disposition of loxapine, amoxapine and ...
2012-01-01 [J. Pharm. Biomed. Anal. 58 , 83-93, (2012)] |
In vitro aerosol characterization of Staccato(®) Loxapine.
2011-01-17 [Int. J. Pharm. 403(1-2) , 101-8, (2011)] |
Inhaled loxapine for agitation revisited: focus on effect si...
2012-03-01 [Int. J. Clin. Pract. 66(3) , 318-25, (2012)] |
The pharmacoepidemiology of antipsychotics for adults with s...
2011-10-01 [Can. J. Psychiatry. 56(10) , 630-4, (2011)] |
Interaction of clozapine and its nitrenium ion with rat D2 d...
2011-02-01 [J. Comput. Aided Mol. Des. 25(2) , 163-9, (2011)] |
Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer
Copyright © 2024 ChemSrc All Rights Reserved